Drug Profile
Research programme: anticancer monoclonal antibodies - GlaxoSmithKline/Oxford BioTherapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Oxford BioTherapeutics
- Developer GSK; Oxford BioTherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer